Having trouble viewing this email? View in your browser.
ESCMID Logo

10 March 2020
WEEKLY NEWS

Dear colleagues,

Please find below the latest edition of ESCMID Weekly News.

With kind regards,
ESCMID Executive Office.

 

EITaF Mailing list: Subscribe to receive COVID-19 outbreak news in your inbox!

Did you know that you can now receive email alerts every time that a new piece of EITaF Outbreak News is published – EITaF is the official ESCMID source for news about the current COVID-19 outbreak.

If you log in to your ESCMID account using your ESCMID login credentials and choose the link ‘Newsletter and Mailing List’ in the right-hand column, You can opt-in to receiving EITaF news alerts.

› Read more

ESCMID Study Group Elections

On Friday, March 6th, we have opened elections for the Executive Committee of the Study Groups listed below. The election procedure consists of 1) a nomination phase in which members can propose themselves as candidate, nominate other members or support nominations. Each nominee must be supported by two other members; 2) an election phase in which the members are invited to vote. The timeline for most Study Groups is the following:

- Nominations: Friday 06/03/2020 - Sunday 22/03/2020
- Approval of the list of nominees: Monday 23/03/2020 - Thursday 26/03/2020
- Elections: Monday 30/03/2020 - Sunday 05/04/2020
- Approval of elected members: Monday 06/04/2020 - Thursday 9/04/2020
- Communication of the results: Monday 13/04/2020
- The new Executive Committee takes office at ECCMID 2020: 18/04/2020 - 21/04/2020

To participate in the election process log in to
my.escmid.org with your ESCMID credentials and click on the “Study Group Elections” icon. Only members with a valid ESCMID membership can take part in the election process. Please be sure to renew immediately your ESCMID membership, should it expire before 6 April 2020.

The Study Groups that have opened or will soon open elections are: ESGS, EFISG, EPASG, ESGAP, ESGBOR, ESGCIP, ESGCP, ESGFOR, ESGHAMI, ESGIB, ESGITM, ESGLI, ESGPHM, ESGREV, EVASG, ESGARS, ESGMYC, EFWISG, ESGIE, ESGCD, ESGMD (one member).

For any question, contact
science@escmid.org

› Read more

ECCMID 2020 update

In the ever-changing environment of the COVID-19 outbreak, ESCMID is working with all stakeholders regarding the 30th ECCMID, 18 – 21 April 2020.
Options for online hosting of the scientific content of the congress are being discussed, and more information regarding these options will be communicated to ESCMID members and ECCMID registrants in the coming days.

ECCMID updates regarding COVID-19 will also be published on the ECCMID website.

› Read more
 

19th ESCMID Summer School – Registrations now open

Registrations are now open for the 19th ESCMID Summer School, to be held in Carcavelos, Portugal from 27 June – 4 July 2020.

Visit the course website to view the programme, as well as other information about the course. Be quick, this course is bound to sell out soon!

› Read more
 

CMI highlight: Treatment of hepatitis D, an unmet medical need

Chronic Hepatitis D (CHD) is the most severe form of viral hepatitides, rapidly leading to cirrhosis, liver dysfunction and hepatocellular carcinoma. There is yet no efficient treatment for Hepatitis D Virus (HDV) infections. Therapy still relies on interferon alfa (IFNα) which was empirically introduced in clinical practice more than 30 years ago.

New therapies against hepatitis D are an urgent need but the challenge is daunting. Targeting host factors critical to virus’s replication is an emerging approach in the treatment of infectious diseases and current efforts against Hepatitis D are addressed at disrupting the viral life-cycle by depriving the HDV of critical biological functions provided to it by the liver cell.

G. Caviglia et al. report on three novel therapeutic strategies that have been devised: targeting the entry into hepatocytes, the assembly of the HDV virion, and the encapsidation of the HDV before export to blood. The authors conclude that the most vulnerable step in the HDV life cycle is the replication process. Fulvestrant exhibited a marked and dose-dependent antiviral effect against HDV; thus, it may represent the first of a class of agents driving host interactions to target the replication process of the HDV.

› Read more
ESCMID Executive Office
P.O. Box 214
4010 Basel
Switzerland
Phone +41 61 5080 173
info@escmid.org
www.escmid.org
Follow ESCMID
Visit us on LinkedIn Visit us on YouTube
 
The ESCMID Newsletter is issued on behalf of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) by the ESCMID Executive Office. It contains announcements of ESCMID-related matters and other information of interest to professionals in the infection field.

Tip: To ensure that you receive the ESCMID newsletter in your inbox, add newsletter@escmid.org to your email program’s address book.

You have received this email as a contact of ESCMID or one of its affiliated societies. You can unsubscribe or change your newsletter subscriptions here.